Everything below concerns visceral adipose tissue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Anguilla - The Scout Association of Anguilla Bermuda - Bermuda Scout Association Cayman Islands - The Scout Association of the Cayman Islands Falkland Islands - Scouting and Guiding in the Falkland Islands Gibraltar - The Scout Association of Gibraltar Montserrat - The Scout Association of Montserrat Saint Helena and Ascension Island - Scouting and Guiding on Saint Helena and Ascension Island Turks and Caicos Islands - The Scout Association of the Turks and Caicos British Virgin Islands - The Scout Association of the British Virgin Islands United States
== Education == Maroon earned his B.S. degree in anatomy and physiology from Indiana University Bloomington in 1961 and his M.D. from the Indiana University School of Medicine (IUSM) in 1965. He received post-graduate education at IUSM (1966), Georgetown University Hospital (1967), John Radcliffe Hospital (1969), Oxford University, England, IUSM (1971), and the University of Vermont College of Medicine (1972).
=== 1970s to 2011 === Though e-commerce on the dark web started around 2006, illicit goods were among the first items to be transacted using the internet, when in the early 1970s students at Stanford University and Massachusetts Institute of Technology used the ARPANET to coordinate the purchase of cannabis. By the end of the 1980s, newsgroups like alt.drugs would become online centres of drug discussion and information; however, any related deals were arranged entirely off-site directly between individuals. With the development and popularization of the World Wide Web and e-commerce in the 1990s, the tools to discuss or conduct illicit transactions became more widely available. One of the better-known web-based drug forums, The Hive, launched in 1997, serving as an information sharing forum for practical drug synthesis and legal discussion. The Hive was featured in a Dateline NBC special called The "X" Files in 2001, bringing the subject into public discourse. From 2003, the "Research Chemical Mailing List" (RCML) would discuss sourcing "Research Chemicals" from legal and grey sources as an alternative to forums such as alt.drugs.psychedelics. However Operation Web Tryp led to a series of website shut downs and arrests in this area. Since the year 2000, some of the emerging cyber-arms industry operates online, including the Eastern European "Cyber-arms Bazaar", trafficking in the most powerful crimeware and hacking tools. In the 2000s, early cybercrime and carding forums such as ShadowCrew experimented with drug wholesaling on a limited scale.
== Potential applications == A wide variety of potential applications have been envisaged. Since magnetic nanoparticles are expensive to produce, there is interest in their recycling or for highly specialized applications. The potential and versatility of magnetic chemistry arises from the fast and easy separation of the magnetic nanoparticles, eliminating tedious and costly separation processes usually applied in chemistry. Furthermore, the magnetic nanoparticles can be guided via a magnetic field to the desired location which could, for example, enable pinpoint precision in fighting cancer.
=== No development reported === Bupropion (amfebutamone; Wellbutrin) – norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator [35] Elcubragistat (ABX-1431; Lu-AG06466) – monoacylglycerol lipase (MAGL) inhibitor [36] EX-597 (KDS-4103; ORG-231295; URB-597) – fatty acid amide hydrolase (FAAH) inhibitor [37] IMM-201 (DAR-901; SRL-172; heat-killed Mycobacterium vaccae strain NCTC-11659) – immunomodulator, immunostimulant, and vaccine [38] Ketamine sublingual (SLS-003; Wafermine) – NMDA receptor antagonist and dissociative hallucinogen [39] Lanicemine (ARL-15896; ARR-15896; BHV-5500; FPL-15896) – NMDA receptor antagonist [40] Research programme: allosteric modulators - Addex Therapeutics – various actions [41] Research programme: cannabis extract therapeutics - Cannabis Science [42] Research programme: cannabinoid-based therapeutics - Axim Biotechnologies (Cannabidiol/Gabapentin; Cannbleph™) [43] Research programme: CNS disorders therapeutics - Sage Therapeutics (SAGE 105; SGE-202; SGE-301; SGE-516) – GABAA receptor modulators and NMDA receptor modulators [44] Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical – undefined mechanisms of action Research programme: serotonin 2A receptor agonists - Bright Minds Biosciences Research programme: tryptamine based therapeutics - PsyBio Therapeutics – serotonin 5-HT2A receptor agonists Topiramate (Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topimax; Topina) – various actions [45]
Sources: en.wikipedia.org
TL 2636 (M-125) is an opioid drug derived from thebaine, one of the bridged oripavine family of drugs known as the Bentley compounds which includes drugs such as buprenorphine and etorphine. TL 2636 is closely related to etorphine and is a similarly potent opioid analgesic and sedative, but at low doses is characterised by producing pronounced nausea and vomiting, with a long duration of action. It was investigated as a potential incapacitating agent but was not successful due to a poor therapeutic index.
=== Hypothesis of genetic and multiple sources for pathogenesis === The two-hit hypothesis of cancer formation has been applied to MASLD , where the disorder may be caused by both a genetic predisposition and two separate and distinct triggering events. However, published medical research describes this as obsolete for MASLD applications as well to not have been determined. The hypothesis of "multiple hit" hypothesis (multiple risk factors as the cause) is considered to be a more accurate depict the pathogenesis of MASLD for those who are genetically predisposed to the disease.
=== Genetically modified crops === The first transgenic crop, which incorporated an insecticidal PIP, contained a gene for the CRY toxin from Bacillus thuringiensis (B.t.) and was introduced in 1997. For the next ca 25 years the only insecticidal agents used in GMOs were the CRY and VIP toxins from various strains of B.t, which control a wide number of insect types. These are widely used with > 100 million hectares planted with B.t. modified crops in 2019. Since 2020 several novel agents have been engineered into plants and approved. ipd072Aa from Pseudomonas chlororaphis, ipd079Ea from Ophioglossum pendulum, and mpp75Aa1.1 from Brevibacillus laterosporus code for protein toxins. The trait dvsnf7 is an RNAi agent consisting of a double-stranded RNA transcript containing a 240 bp fragment of the WCR Snf7 gene of the western corn rootworm (Diabrotica virgifera virgifera).
6 February – Around eight million people on means tested benefits begin to receive the final scheduled cost-of-living payment from the UK government, as Sunak tells the BBC the financial pressures on households are beginning to ease. 7 February The government announces that dentists will be offered a £20,000 bonus to work in the areas of England with the poorest access to NHS care. Data published by Halifax Bank indicates that UK house prices increased by 2.5% in January 2024 when compared to the same month in 2023. The Met Office issues two amber snow warnings for the following day covering north Wales, north-west Shropshire, the Peak District and south Pennines. 8 February The UK government confirms that more than 100 school buildings containing reinforced autoclaved aerated concrete will be rebuilt or refurbished. Sir Keir Starmer insists he has no choice but to ditch Labour's £28 billion a year green investment pledge. 9 February Weather warnings remain in place as snow and rain continue to fall across the UK. Police tell reporters they believe that Abdul Shakoor Ezedi may have drowned in the River Thames, based on CCTV of the suspect at Chelsea Bridge. The Duke of Sussex settles his remaining phone hacking claims against Mirror Group Newspapers, with the newspaper agreeing to pay his legal costs along with around £300,000 in compensation. 10 February Police begin a search of the River Thames for the body of Abdul Shakoor Ezedi, the Clapham chemical attack suspect. A light aircraft crashes into the garden of a property in Bodffordd, Anglesey.
Sources: en.wikipedia.org
== Signal transduction == Through diverse means, extracellular ligand binding will typically cause or stabilize receptor dimerization. This allows a tyrosine in the cytoplasmic portion of each receptor monomer to be trans-phosphorylated by its partner receptor, propagating a signal through the plasma membrane. The phosphorylation of specific tyrosine residues within the activated receptor creates binding sites for Src homology 2 (SH2) domain- and phosphotyrosine binding (PTB) domain-containing proteins. Specific proteins containing these domains include Src and phospholipase Cγ. Phosphorylation and activation of these two proteins on receptor binding lead to the initiation of signal transduction pathways. Other proteins that interact with the activated receptor act as adaptor proteins and have no intrinsic enzymatic activity of their own. These adaptor proteins link RTK activation to downstream signal transduction pathways, such as the MAP kinase signalling cascade. An example of a vital signal transduction pathway involves the tyrosine kinase receptor, c-met, which is required for the survival and proliferation of migrating myoblasts during myogenesis. A lack of c-met disrupts secondary myogenesis and—as in LBX1—prevents the formation of limb musculature. This local action of FGFs (Fibroblast Growth Factors) with their RTK receptors is classified as paracrine signalling. As RTK receptors phosphorylate multiple tyrosine residues, they can activate multiple signal transduction pathways.
=== Other wins (11) === 1955 Egyptian Matchplay 1965 World Series of Golf, NTL Challenge Cup (Canada), World Cup of Golf, World Cup of Golf Individual Trophy 1968 World Series of Golf 1972 World Series of Golf 1977 World Cup of Golf Individual Trophy 1979 PGA Grand Slam of Golf (shared title with Andy North) 1983 Skins Game 1986 Fred Meyer Challenge (with Greg Norman - team shared title with Peter Jacobsen and Curtis Strange)
It chose to follow a single character to aid the immersion, creating the isolation of a vampire unable to trust any other character. This aided the story and compensated for the technical issues of allowing multiple player characters. Choice is a significant aspect of the game, requiring a non-linear design to accommodate the customized characters. Level design began with a list of factors such as Disciplines, stealth, and feats. Each area had to be viable for a shooting character (sufficient ammunition), a discipline-focused character (sufficient blood sources to keep the powers fueled), and a melee specialist (to reach enemies without being killed), with stealth options and option combinations. Level design began with a focus on stealth, considering the positioning of guards and the character's potential stealth capability at that point in the game. Then direct, combat-heavy, and dialogue paths were added. The amusement arcade area was to feature playable versions of Activision arcade games such as Pitfall!, though the idea was abandoned due to time constraints. Director Leonard Boyarsky considered the animation system important in the team's choice of the Source engine. The integrated "faceposer" tool allowed Troika to customize facial animations, expressions, gestures, and lip-synching, eliminating the need to explain what a character was doing. Every non-player character required a voiceover, which helped Troika define its characters more quickly.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.